Focusing on ground-breaking medicines to address chronic progressive diseases, including in rheumatology and dermatology.

Investing in new pathways, technologies and approaches to tackle the most widespread and debilitating cancers.

Discovering compounds that have the potential to treat chronic disabling neurological conditions and impairments, including MS, Parkinson’s Disease and Alzheimer’s.

Partnering with patient advocates and leading stakeholders to help address unmet needs across the world for people living with HIV-1 and hepatitis C.

Seeking solutions for a range of diseases that currently have few or no treatments, including cystic fibrosis, endometriosis, uterine fibroids and diabetic nephropathy.